NCT06491563View on ClinicalTrials.gov

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
For Treatment of Chronic Hepatitis B Virus Infection
Interventions
BIOLOGICAL

BRII-179

BRII-179 will be given via intramuscular injection

DRUG

BRII-835 (VIR-2218)

BRII-835 will be given via subcutaneous injection

BIOLOGICAL

PEG-IFNα

PEG-IFNα will be given via subcutaneous injection

Trial Locations (12)

100000

Investigative Site 86004, Beijing

Investigative Site 86009, Beijing

200000

Investigative Site 86003, Shanghai

Investigative Site 86008, Shanghai

310000

Investigative Site 86005, Hangzhou

361000

Investigative Site 86015, Xiamen

510000

Investigative Site 86001, Guangzhou

Investigative Site 86013, Guangzhou

518000

Investigative Site 86002, Shenzhen

528000

Investigative Site 86012, Foshan

610000

Investigative Site 86007, Chengdu

Investigative Site 86011, Chengdu

Sponsors
All Listed Sponsors
collaborator

Vir Biotechnology, Inc.

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY